Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 5829-5833, September 15, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seva, C.
Right arrow Articles by Vaysse, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seva, C.
Right arrow Articles by Vaysse, N.

Lorglumide and Loxiglumide Inhibit Gastrin-stimulated DNA Synthesis in a Rat Tumoral Acinar Pancreatic Cell Line (AR42J)1

Catherine Seva2, Jean Luc Scemama, Marie José Bastié, Lucien Pradayrol and Nicole Vaysse

Institut National de la Santé et de la Recherche Medicale, Unité 151, C.H.U. Rangueil, Bat. L3, 31054 Toulouse Cedex, France

Many reports emphasized the role of gastrin as growth factor on normal gastrointestinal mucosa and pancreas. In the present study, we analyzed the proliferative effects of cholecystokinin (CCK) and gastrin peptides on a rat tumoral pancreatic cell line, AR42J, which possesses both CCKA and CCKB receptor subtypes.

The results showed a good correlation between the binding of gastrin to CCKB receptor [Kd 1.125 ± 0.3 (SD) nM] and its ability to either induce ornithine decarboxylase activity [50% effective concentration, 0.6 ± 0.3 nM] and [3H]-thymidine incorporation [50% effective concentration, 2 ± 0.4 nM]. Furthermore, the ability of different cholecystokinin and gastrin antagonists such as proglumide and asperlicin derivatives (respectively, CR1409, CR1505, and L364,718) were tested. We found that all antagonists displaced 125I-labeled gastrin binding, with the following order of potencies: L364,718 > CR1409 > CR1505 > proglumide. Furthermore, the 50% inhibitory concentration of CR1409 and CR1505 to inhibit gastrin stimulated ornithine decarboxylase activity (an early event involved in cell proliferation) and [3H]thymidine incorporation were in agreement with their constants of inhibition (K1) on gastrin binding. The L364,718 compound, at a concentration which fully occupied the CCKA without affecting the CCKB, had no effect on gastrin stimulated ornithine decarboxylase activity and [3H]thymidine incorporation. In addition, this compound appeared to be a full agonist on CCKB receptor.

These results confirm the implication of the CCKB receptor in the proliferative response of AR42J cells to gastrin.

1 The present work was supported by grants from the Association pour la Recherche sur le Cancer (6414), EEC (ST2 J00 1-3F), and Région Midi-Pyrénées (8700777).

2 To whom requests for reprints should be addressed, at INSERM U 151, C.H.U. Rangueil, Bat. L3, 31054 Toulouse, France.

Received 3/ 6/90. Accepted 6/ 4/90.




This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. S. Steigedal, T. Bruland, K. Misund, L. Thommesen, and A. Laegreid
Inducible cAMP early repressor suppresses gastrin-mediated activation of cyclin D1 and c-fos gene expression
Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G1062 - G1069.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. Thommesen, E. Hofsli, R. H. Paulssen, M. W. Anthonsen, and A. Lagreid
Molecular mechanisms involved in gastrin-mediated regulation of cAMP-responsive promoter elements
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1316 - E1325.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Thommesen, K. Norsett, A. K. Sandvik, E. Hofsli, and A. Lagreid
Regulation of Inducible cAMP Early Repressor Expression by Gastrin and Cholecystokinin in the Pancreatic Cell Line AR42J
J. Biol. Chem., February 11, 2000; 275(6): 4244 - 4250.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Daulhac, A. Kowalski-Chauvel, L. Pradayrol, N. Vaysse, and C. Seva
Src-family Tyrosine Kinases in Activation of ERK-1 and p85/p110-phosphatidylinositol 3-Kinase by G/CCKB Receptors
J. Biol. Chem., July 16, 1999; 274(29): 20657 - 20663.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Kowalski-Chauvel, L. Pradayrol, N. Vaysse, and C. Seva
Gastrin Stimulates Tyrosine Phosphorylation of Insulin Receptor Substrate 1and Its Association with Grb2 and the Phosphatidylinositol 3-Kinase
J. Biol. Chem., October 18, 1996; 271(42): 26356 - 26361.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
C Seva, C. Dickinson, and T Yamada
Growth-promoting effects of glycine-extended progastrin
Science, July 15, 1994; 265(5170): 410 - 412.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.